This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Victor E. Pricolo, MD; Sydney D. Finkelstein, MD; Katrine Hansen, MD; Bernard F. Cole, PhD; Kirby I. Bland, MD

Arch Surg. 1997;132(4):371-375.

Abstract
Objective
To evaluate the impact of p53 gene mutations on long-term survival in patients with intermediate stage carcinoma of the colon.

Design
Retrospective cohort study; median follow-up of 87 months.

Setting
Tertiary care academic medical center.

Patients
Mutational analysis was conducted in a single institution in 141 consecutive patients with resected stage II (n=71) and stage III (n=70) colon carcinoma. Archival pathology specimens were analyzed for point mutations of exons from the p53 gene by means of amplification and direct sequencing by polymerase chain reaction.

Main Outcome Measures
The impact of p53 mutations and of adverse histopathologic features (ie, poor differentiation, lymphovascular invasion, or mucin production) on patient survival.

Results
Median overall survival was 64 months (95 months for patients with stage II and 34 months for patients with stage III colon carcinoma; P=.001). Presence of a p53 mutation was the single most important risk factor associated with poorer survival in both patients with stage II (P=.02) and stage III colon carcinoma (P=.006) throughout the follow-up period. A p53 mutation increased the risk of death by 2.82 times in patients with stage II and by 2.39 times in patients with stage III colon carcinoma. There was an additive effect on the cumulative risk of death between p53 mutations and adverse histopathologic variables.

Conclusions
The presence of p53 mutations carries an independent adverse prognostic value in colon cancer. These findings imply that the applicability of mutational analysis in clinical practice is likely to affect therapeutic choices in the future.

Arch Surg. 1997;132:371-375

Author Affiliations
From the Department of Surgery, Rhode Island Hospital and Brown University, Providence.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients
Westra et al.
JCO 2005;23:5635-5643.
ABSTRACT | FULL TEXT  

Homogeneous Amplification and Mutation Scanning of the p53 Gene Using Fluorescent Melting Curves
Millward et al.
Clin. Chem. 2002;48:1321-1328.
ABSTRACT | FULL TEXT  

Analysis of the p53/BAX Pathway in Colorectal Cancer: Low BAX Is a Negative Prognostic Factor in Patients With Resected Liver Metastases
Sturm et al.
JCO 1999;17:1364-1364.
ABSTRACT | FULL TEXT